From plenary and award lectures delivered by some of the top thought-leaders and pioneers in breast cancer research and care to late-breaking and practice-changing findings from some of the most cutting-edge research being conducted in the field, the SABCS 2022 Program Committee has outdone itself in assembling a robust program with something for everyone.

SABCS Meeting News asked members of the Program Planning Committee about the value of SABCS and the quality of this year’s program. Here, committee members Sibylle Loibl, MD, PhD, and Fabrice André, MD, PhD, told us what they are looking forward to at SABCS 2022.

What do you expect will be some of the most talked-about topics at SABCS 2022?

Dr. Loibl: Treatment with antibody-drug conjugates will most certainly be a hot topic, as will the role of mutations and new definitions of subgroups in breast cancer. Locoregional therapy in general will be a well-covered topic at SABCS this year.

Dr. André: I agree that the latest updates and new indications for antibody-drug conjugates in breast cancer treatment will be of great interest to everyone, as well as the latest data on novel agents and targeted therapy for ER+ breast cancer patients.

What are you most looking forward to at SABCS 2022?

Dr. Loibl: As always, I look forward to any new research findings and new information that informs us and helps us better treat our patients. The sheer amount of new data focused only on breast cancer and the ability to hear all the oral presentations and see all of the posters at SABCS is invaluable. That’s why people come from around the world to attend SABCS.

Dr. André: I look forward to SABCS every year for the wide range of original presentations of new and late-breaking data, much of which is being presented for the first time. SABCS is also the ideal place to network and exchange ideas with colleagues and start new collaborative projects.

Dr. Loibl is Chief Executive Officer and Chair of the German Breast Group, and Associate Professor of Obstetrics and Gynecology at Goethe University Frankfurt.

Dr. André is Director of Research and consultant medical oncologist in breast cancer at Gustave Roussy Cancer Campus, Villejuif, France, and Professor of Medicine at Université Paris-Saclay.